Conference Coverage

ReachMD
  • 5,0 (1)
  • SCIENCES
  • TOUS LES JOURS

ReachMD brings you the latest research, announcements, and conversations from the most important medical conferences around the world. Join us on the conference floor with keynote speakers, experts, and opinion leaders.

  1. -4 J

    Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers

    Host: Ryan Quigley A new multicenter study highlights how serum and CSF biomarkers can refine prognostic accuracy and guide treatment strategies in multiple sclerosis (MS). ReachMD's Ryan Quigley explains key findings and provides insights on how integrating these biomarkers at diagnosis could move MS care toward more personalized and effective interventions. This topic was also discussed at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

  2. -4 J

    Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning

    Host: Hallie Blevins, PhD. Early resistance to hydroxyurea in patients with polycythemia vera (PV) is associated with higher risks of thromboembolic complications, disease progression, and mortality. The PV-AIM study applied machine learning to real-world data and identified simple lab-based predictors that stratify patients by risk, and these findings were later validated in the HU-F-AIM trial. Hear from ReachMD's Dr. Hallie Blevins as she dives into the results and explains implications for optimized therapy and improved long-term outcomes.

  3. -5 J

    Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma

    Host: Ryan Quigley In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.

  4. -6 J

    Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study

    Host: Marlene Mimi Maeusli, PhD. A recent Danish population-based study evaluating real-world outcomes of ibrutinib in relapsed or refractory mantle cell lymphoma (MCL) found lower efficacy and tolerability compared to clinical trials, particularly among older patients and those with high-risk disease features. In this AudioAbstract, ReachMD's Dr. Mimi Maeusli explains how this evidence is reshaping our view of ibrutinib's clinical utility.

  5. 10 SEPT.

    Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers

    Guest: Paola Marignani, PhD, EMBA While smoking remains a key risk factor for lung cancer, up to 25 percent of cases occur in people who have never smoked, leaving significant gaps in our understanding of causation and diagnostics. Dr. Paola Marignani explores emerging discoveries in gene variants unique to never-smokers, uncovered through single-cell RNA sequencing and machine learning. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.

  6. 9 SEPT.

    From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care

    Host: Ryan Quigley The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.

  7. 9 SEPT.

    Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing

    Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

  8. 9 SEPT.

    The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption

    Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Tout afficher (269)

À propos

ReachMD brings you the latest research, announcements, and conversations from the most important medical conferences around the world. Join us on the conference floor with keynote speakers, experts, and opinion leaders.

Informations

  • Création
    ReachMD
  • Années d’activité
    2014 - 2025
  • Épisodes
    269
  • Classification
    Tous publics
  • Copyright
    © Copyright 2025 ReachMD. All rights reserved.
  • Site web de l’émission
    Conference Coverage

Plus de contenus par ReachMD

Vous aimeriez peut‑être aussi